Report Overview:
In this emerging in the form of cooperation, biological medicine industry further extended to the biological agents in the form of outsourcing cooperation contract development and manufacturing organization (CDMO) mode, the CDMO from preclinical studies and clinical trials to commercial production stage and the enterprise research and development, procurement, production, such as depth of the whole supply chain system docking, provide enterprises with innovative technology research and development and large-scale production services, in the higher value-added technology output instead of the pure output capacity.
This report provides a deep insight into the global Biologics Contract Development and Manufacturing Organization(CDMO) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
Market Value:
The global Biologics Contract Development and Manufacturing Organization(CDMO) market size was estimated at USD 11310 million in 2024 and is projected to reach USD 28697.66 million by 2032, exhibiting a CAGR of 10.90% during the forecast period.
By Types:
• Biologics Contract Development Services
• Biologics Contract Manufacturing Services
By Applications:
Big Pharma
Small Pharma Generic Pharma
Key players include:
• Lonza
• Hansen
• Boehringer Ingelheim BioXcellence
• Thermo Fisher Scientific
• Samsung BioLogics
• AGC Biologics
• Including or Excluding key companies relevant to your analysis.
